MGNX

MacroGenicsdistress 4/10 · elevated risk

$4.14-4%today-15% from 52w high

macrogenics.com293 employeesFounded 2000Rockville, MDBiotechnology

Oncology 2

Lead: Leukemia · est. market ~$15B (approx, global)

Revenue

$21M

Liquidity

$67M

Runway

0.9 yrs

Shares 1y

+1%

Price & events

+135.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.8%

+0.4%

-11.8%

+30.1%

+129.8%

+128.5%

-22.4%

-84.0%

-81.4%

All

Overview

Market Cap: $262.91M
Volume: 33.87K
52 Week Range: $1.33 – $4.86
Total Shares: 63.56M
Float Shares: 55.88M
Short %: 10.81%
% Held by Insiders: 3.43%
% Held by Institutions: 71.08%
RVOL: 0.03x
Beta: 1.18

Pipeline stages · 5 programs

MGC028

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-11

MGD024

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-11

Lorigerlimab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-07

MGC026 Dose Escalation, MGC026 Dose for Expansion

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-05

vobramitamab duocarmazine, lorigerlimab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 6 trials · 4 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-11 Estimated 50% readout ~2026-12-01	Phase 1	MGC028	Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma	—	recruiting
2026-11 Estimated 50% readout ~2026-12-01	Phase 1	MGD024	Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia	—	recruiting
2027-07 Estimated 50% readout ~2027-08-15	Phase 2	Lorigerlimab	Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer	—	recruiting
2028-05 Estimated 50% readout ~2028-05-31	Phase 1	MGC026 Dose Escalation, MGC026 Dose for Expansion	Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)	—	recruiting
2026-02-19	Phase 2	lorigerlimab, docetaxel, Prednisone	Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule	154	completed

Show all 6 trials · 1 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2025-06-24	Phase 1	vobramitamab duocarmazine, lorigerlimab	Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma	31	completed